… In contrast, of 14 617 nursing home patients in the current study, 5678 were prescribed with
… and nirmatrelvir/ritonavir for 483 patients. Molnupiravir and nirmatrelvir/ritonavir users had …

… In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12 years or older
with … We aimed to establish the effectiveness of nirmatrelvir–ritonavir in preventing hospital …

… Utilizing a multivariable Cox model with time-updated exposure to nirmatrelvir/ritonavir,
nirmatrelvir/ritonavir was associated with a reduction in the hazard of COVID-19 hospitalization (…

… that nirmatrelvir–ritonavir was effective in preventing progression to severe COVID-19. Our
objective was to evaluate the effectiveness of nirmatrelvir–ritonavir … of nirmatrelvir–ritonavir on …

… some skilled nursing facilities or elder home care programs that … care system encompassing
9 hospitals, hospitalizations outside our system were not included. Positive results on home …

… (nirmatrelvir-ritonavir and molnupiravir), as well as new resident COVID-19 weekly cases…
All Medicare-certified nursing homes were required to submit information to NHSN. Facility …

… the trial cohort to treatment with nirmatrelvir-ritonavir to identify DDIs with … time of
nirmatrelvir-ritonavir exposure, and/or (2) deprescribing at the approximate time of …

… Patients receiving long-term care or support were defined as those … care facility, commuting
to the facility, or with nurses visiting their homes routinely to administer medical or living care. …

… nirmatrelvir/ritonavir. Three hospitalizations were recorded in the molnupiravir (2.1%) group
and one in the nirmatrelvir/ritonavir (… was 8 days in the nirmatrelvir/ritonavir group vs. 10 days …

… Nirmatrelvir/ritonavir (Paxlovid, Pfizer) is a combination protease inhibitor that prevents
viral … This analysis summarises what is currently known about nirmatrelvir/ritonavir and the …